you, Todd. Thank
quarter support important as structure several performance years worked the point have to of and we efficient to commercial last XXXX. by an the transition operating focus quarters needs has by profile strong over of products an and our to for and The the marks profitability.
QX a our are us, of proprietary expectations performance that the been company of operating was for reiterating the financial With realigned inflection another driven we third the business quarter VIVITROL behind our productive business X results continued Alkermes, LYBALVI drive financial solid highlighted for on the and efficiency.
portfolio, with last million, product year. were For the to driven net third million which the year-over-year.
Starting quarter, $XXX.X in we revenues our XX% in period sales compared quarter $XXX.X $XX.X by VIVITROL, of proprietary same grew million total generated the
remained the million for the month-on-hand ARISTADA same LYBALVI, a were And sales $XX.X stable QX sales million million year. to our Across products, family, $XX.X basis. million $XX.X commercial compared last net on $XX.X For net in product last compared inventory were for to proprietary year. period
were and royalty In third we $XXX.X recorded revenues year. to and the products manufacturing from our to business. compared million long-acting million on $XX.X Moving last the $XX.X QX Revenues INVEGA manufacturing of royalty quarter, million. for
year. and in royalties financial the our disclosed expectations, in reflected SUSTENNA on U.S. ended mid-August our INVEGA in of of previously net As sales this
represent of the revenues FAMPYRA. related activities, any expect during revenues the in we to $XX.X to of continue revenues timing HAFYERA million INVEGA VUMERITY manufacturing of on FAMPYRA the Due did royalties manufacturing will INVEGA record the we outside of TRINZA to year. compared from $XX.X QX of conclusion associated long-acting to This approximately our the and and $XX in INVEGA products manufacturing related the FAMPYRA and on U.S.
Revenues last quarter, million million for were receive obligations to but We not U.S. sales QX. will net
year. to ALKS continuing primarily late clinical XXXX last million our R&D last last of to turn This support QX and QX to products. million and our our I'll program were Now $XX.X business million separation the goods compared operating $XX.X Cost compared commercial financial proprietary million consisted focused results from expenses our neuroscience activities programs, our $XX.X year. oncology for in of of operations expenses sold year. the related were for for investments $XX.X development following to
We of million in $XXX.X remain to $XXX.X for compared year.
SG&A this last the range expect million R&D end the year. through to QX expenses expense were
decrease the we expenses expect the primarily of fourth quarter, activities. ahead, timing SG&A in to promotional reflecting Looking and mix commercial
of focus net to during continue million. the non-GAAP $XX.X of on profitability. from net quarter, and $XXX.X operations of GAAP And continuing delivered $XXX.X million We driving income continuing EBITDA million, we from operations from continuing income operations third
financial in investments. to Turning our sheet. strong a position $XXX.X million in balance the third and quarter total with ended We cash
million we repurchase X.X approximately as shares $XXX program market year. During share million remaining authorized repurchase dependent million repurchase business. of the this $XXX part $XXX of opportunistically authorization, shares the deployed to may forward, on With conditions quarter, going the the of million and capital we earlier needs
business strong position we on for be against of financial across in profitability opportunities to while business the manage solid shareholder spend made next I'm a going we we XXXX.
Switching the as will a key financial strategic, in have plan XXXX, investment our significant our In year. operational value. that drivers growth the and plans our and minute flow to believe increasing to progress the cash deliver and are We execute priorities for gears,
Biogen growth But proprietary we into mind.
In XXXX we increase be top XXXX, the we transition driven the in within portfolio, provide our modestly will the support line will revenues our increase idiopathic revenues with ALKS highlight we in investment ongoing studies the early previously planned in reflecting the expect today, million success streams, advance and as expected and hypersomnia in in our by FAMPYRA commercial will X manufacturing INVEGA our sales LYBALVI few clinic as overall will and psychiatry to expect costs on ALKS February. our to Phase these in XXXX.
Primarily keep operating expectations I we $XXX expect the royalties expand dynamics by primarily driven ARISTADA. in of of of royalty net manufacturing growth will detailed XXXX XXXX. to our factors announced We commercial revenue a manufacturing of impact and the namely U.S. XXXX, of and and conclusion manufacturing Collectively, royalty VUMERITY by footprint SUSTENNA approximately and considerations
to committed profitability in $XXX to and million next expect of than deliver maintaining cash-generating robust year. we're together, Taken business EBITDA more a
will as a profile serve significant years transformation foundation now our financial hand strong Rich. demonstrate XXXX the the Our of growth and several last and company to the future the that, for I'll over call performance.
With financial
